JO
PTCT icon

John Overdeck’s PTC Therapeutics PTCT Stock Holding History

John Overdeck’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,900
Closed -$219K – 3418
2020
Q1 		$219K Buy
+4,900
New +$247K ﹤0.01% 2590

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

John Overdeck's PTCT Position: Q2 2026 in Review

John Overdeck reduced its PTC Therapeutics (PTCT) stake by 61% in Q2 2026, selling an estimated $1.19M and leaving 10,654 shares worth $869K. The position accounts for ﹤0.01% of the portfolio, ranked #3713.

John Overdeck first reported a position in PTCT in Q1 2015 and has held it in 26 quarters since. The position peaked at $17.8M in Q1 2018. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • John Overdeck held 10,654 shares of PTC Therapeutics worth $869K as of Q2 2026.
  • John Overdeck sold 16,456 PTC Therapeutics shares in Q2 2026, an estimated $1.19M.
  • PTC Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3713 holding.
  • John Overdeck first reported a position in PTC Therapeutics in Q1 2015 and has held it in 26 quarters since.
  • John Overdeck's PTC Therapeutics position peaked at $17.8M in Q1 2018.
  • 380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.